These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8854016)

  • 21. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.
    Richardson G; Linkins RW; Eames MA; Wood DJ; Campbell PJ; Ankers E; Deniel M; Kabbaj A; Magrath DI; Minor PD
    Bull World Health Organ; 1995; 73(6):769-77. PubMed ID: 8907770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thermostabilization of live virus vaccines by heavy water (D2O).
    Wu R; Georgescu MM; Delpeyroux F; Guillot S; Balanant J; Simpson K; Crainic R
    Vaccine; 1995 Aug; 13(12):1058-63. PubMed ID: 7491812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice.
    Levenbook I; Nomura T
    Lab Anim Sci; 1997 Apr; 47(2):118-20. PubMed ID: 9150487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory requirements for veterinary vaccine stability in the European Community.
    Fawthrop D
    Dev Biol Stand; 1996; 87():319-27. PubMed ID: 8854032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On stability of oral poliovirus vaccines.
    Mauler R; Gruschkau H
    Dev Biol Stand; 1978; 41():267-70. PubMed ID: 38157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.
    Grassly NC; Jafari H; Bahl S; Durrani S; Wenger J; Sutter RW; Aylward RB
    J Infect Dis; 2009 Sep; 200(5):794-801. PubMed ID: 19624278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible global strategies for stopping polio vaccination and how they could be harmonized.
    Cochi SL; Sutter RW; Aylward RB
    Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing the stability of live oral attenuated bacterial vaccines.
    Cryz SJ; Pasteris O; Varallyay SJ; Fürer E
    Dev Biol Stand; 1996; 87():277-81. PubMed ID: 8854028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.
    Breiman RF; Brooks WA; Goswami D; Lagos R; Borja-Tabora C; Lanata CF; Londoño JA; Lum LC; Rappaport R; Razmpour A; Walker RE; Gruber WC; Forrest BD
    Vaccine; 2009 Sep; 27(40):5472-9. PubMed ID: 19616493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2.
    Chen CH; Wu R; Roth LG; Guillot S; Crainic R
    Arch Biochem Biophys; 1997 Jun; 342(1):108-16. PubMed ID: 9185619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau.
    Aaby P; Hedegaard K; Sodemann M; Nhante E; Veirum JE; Jakobsen M; Lisse I; Jensen H; Sandström A
    Vaccine; 2005 Feb; 23(14):1746-51. PubMed ID: 15705481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines: World Health Organization versus Federal Drug Administration recommended formula.
    Khalil MK; al-Mazrou YY; al-Ghamdi YS
    East Mediterr Health J; 2000 Jul; 6(4):644-51. PubMed ID: 11794070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monovalent polio immunisation--a strategy for India.
    Chatterjee A; Chawla A
    J Indian Med Assoc; 2005 Dec; 103(12):682-5. PubMed ID: 16821665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
    Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The WHO Global Programme for Vaccines and Immunization Vaccine Trial Registry.
    Robertson SE; Mayans MV; Horsfall S; Wright PF; Clemens J; Ivanoff B; Lambert PH
    Bull World Health Organ; 1997; 75(4):295-305. PubMed ID: 9342888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine.
    Dragunsky E; Taffs R; Chernokhvostova Y; Nomura T; Hioki K; Gardner D; Norwood L; Levenbook I
    Biologicals; 1996 Jun; 24(2):77-86. PubMed ID: 8889053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.